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Abstract
Background: Paediatric end-of-life care is challenging and requires a high level of professional expertise. It is important
that healthcare teams have a thorough understanding of paediatric subspecialties and related knowledge of disease-
specific aspects of paediatric end-of-life care. The aim of this study was to comprehensively describe, explore and
compare current practices in paediatric end-of-life care in four distinct diagnostic groups across healthcare settings
including all relevant levels of healthcare providers in Switzerland.
Methods: In this nationwide retrospective chart review study, data from paediatric patients who died in the years 2011 or
2012 due to a cardiac, neurological or oncological condition, or during the neonatal period were collected in 13 hospitals,
two long-term institutions and 10 community-based healthcare service providers throughout Switzerland.
Results: Ninety-three (62%) of the 149 reviewed patients died in intensive care units, 78 (84%) of them following
withdrawal of life-sustaining treatment. Reliance on invasive medical interventions was prevalent, and the use of
medication was high, with a median count of 12 different drugs during the last week of life. Patients experienced
an average number of 6.42 symptoms. The prevalence of various types of symptoms differed significantly among
the four diagnostic groups. Overall, our study patients stayed in the hospital for a median of six days during their
last four weeks of life. Seventy-two patients (48%) stayed at home for at least one day and only half of those
received community-based healthcare.
(Continued on next page)
* Correspondence: karin.zimmermann@unibas.ch
1Department Public Health (DPH), Nursing Science, University of Basel,
Bernoullistrasse 28, 4056 Basel, Switzerland
2Paediatric Palliative Care, University Children’s Hospital Zurich, Children’s
Research Center CRC, Steinwiesstrasse 75, 8032 Zurich, Switzerland
Full list of author information is available at the end of the article
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Zimmermann et al. BMC Pediatrics  (2018) 18:67 
https://doi.org/10.1186/s12887-018-1021-2
(Continued from previous page)
Conclusions: The study provides a wide-ranging overview of current end-of-life care practices in a real-life setting of
different healthcare providers. The inclusion of patients with all major diagnoses leading to disease- and prematurity-
related childhood deaths, as well as comparisons across the diagnostic groups, provides additional insight and
understanding for healthcare professionals. The provision of specialised palliative and end-of-life care services in
Switzerland, including the capacity of community healthcare services, need to be expanded to meet the specific needs
of seriously ill children and their families.
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Background
Despite continued advancements in medical care and
improved (expected) survival, infant and childhood
deaths due to complex chronic conditions (CCC) or pre-
maturity are inevitable [1]. Deaths during the first year
of life constitute approximately 50% of disease-related
infant and childhood deaths in developed countries, the
causes of which include perinatal complications, prema-
turity, or congenital anomalies [2, 3]. Beyond the age of
one year, the three most common life-limiting CCCs are
neurological/neuromuscular and cardiovascular condi-
tions (including genetic disorders), and malignancies [4,
5]. The majority of disease- and prematurity-related
deaths occur in hospitals, [6, 7], and for children dying
at home, hospital use in their terminal stage is high [1,
4]. Symptom burden and reliance on medical technology
has been reported to be considerable [3, 8]. Circum-
stances and characteristics of deaths, however, are
known to vary by age and medical conditions [1, 4].
Paediatric palliative care (PPC) emerged as a medical
subspecialty aimed at meeting the specific needs of ser-
iously ill children and their families. According to the
World Health Organization (WHO) “palliative care is an
approach that improves the quality of life of patients and
their families facing the problem associated with life-
threatening illness, through the prevention and relief of
suffering by means of early identification and impeccable
assessment and treatment of pain and other problems,
physical, psychosocial and spiritual” [9]. More specific-
ally and as part of palliative care, the term end-of-life
(EOL) care refers to care when death is imminent [10].
Meeting the needs of affected children and their families
requires a wide-ranging and integrative approach from a
compassionate and skilled multidisciplinary team [11].
PPC and EOL care should be provided in all settings
where it is required [12]; although, specialised PPC
teams are mostly hospital based [13]. A thorough under-
standing of paediatric subspecialties and related know-
ledge of disease-specific aspects of paediatric EOL are
needed. This understanding should go beyond the hori-
zon of a single hospital and take into account the
heterogeneous settings where care can be provided
(tertiary settings, general hospitals, paediatric primary
care and in the community). There is not much evidence
on which to base best practice, and most existing studies
focus on specific diagnostic groups or specific care set-
tings [1, 14, 15]. It was therefore the aim of this national
study to comprehensively describe, explore and compare
current practices in paediatric EOL care in four distinct
diagnostic groups (cardiology, neonatology, neurology
and oncology) across healthcare settings including all
relevant levels of healthcare providers in Switzerland.
Methods
Study design
This retrospective chart review was part of PELICAN
(Paediatric End-of-LIfe-CAre Needs in Switzerland), a na-
tionwide study “to provide comprehensive information
and to understand the current practice of EOL care (i.e. in
this study and similar to other studies, the last 4 weeks of
life prior to death [16]) in paediatric settings in
Switzerland (hospital and community care) and to explore
and describe parental perspectives and the perspectives of
the healthcare professionals involved” [17]. Human
Research Ethics Committees from the 11 Swiss cantons in
which the study took place approved the PELICAN study.
Parents who had lost a child due to a cardiac, neurological
or oncological condition or during the neonatal period
(independent of the underlying condition) in the years
2011 and 2012 were invited to participate. Neonates <
24 h of life and patients > 18 years were excluded.
Information on how, where and when recruitment took
place is described in detail elsewhere [18].
Setting and data collection
Data from all eligible patients, whose parents had
consented to the review of their child’s medical chart,
were collected in 13 hospitals, 2 institutions and 10
community-based healthcare service providers through-
out Switzerland. Among the 13 hospitals, there were 5
tertiary paediatric centres, 4 dedicated children’s
hospitals, 3 general hospitals with paediatric units and 1
tertiary care centre with a neonatal intensive care unit.
A multiprofessional PPC team was available in two ter-
tiary paediatric centres and one dedicated children’s hos-
pital; no paediatric hospices exist in Switzerland.
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Data collection was conducted mainly by the first au-
thor, who also developed the coding manual and all case
report forms as well as instructing and supervising five
assistants, who supported data collection [19]. The
coding manual was developed within the PELICAN
study group [17] and pilot tested with 10 children who
were treated in 5 different hospitals and died in the year
2010. In accordance with this study’s definition of EOL
care as care during the last four weeks of life, data
collection was restricted to the 28 days prior to the
child’s death. All extracted data was entered into secu-
Trial®, a browser-based electronic data capture system
(InterActive Systems, Berlin, Germany). During the first
two months of data collection, 5 % of the medical re-
cords reviewed by one of the five assistants were
randomly selected and audited by KZ by performing a
dual review. Any data entry discrepancies were checked
for its nature of assessment error. No systemic data
entry errors were detected. There were very few data
entry discrepancies and those that occurred were almost
always related to mixed documentation quality in the
medical records that left room for interpretation, e.g.,
change of do-not-resuscitate (DNR) order. Emerging
questions around those inconsistencies were continu-
ously discussed among data collectors. Variable instruc-
tions in the manual were revised as needed to ensure
the quality of ongoing data extraction and reduce the
likelihood of inter-rater discrepancies [19].
Variables
The following data were collected for this study: (1)
demographics (age, gender); (2) diagnostic information
(the underlying diagnosis primarily responsible for the
patient’s death, gestational age for newborns only, time
since diagnosis, and whether the diagnosis was made
prenatally); (3) circumstances of death (place of death,
occurrence of resuscitation, existence of DNR orders
and whether these orders changed during the last four
weeks of life, and treatment withdrawal); (4) interven-
tions (at least once during the last four weeks of life,
Yes-No: anaesthesia, e.g., surgery, imaging; ventilation;
central access device; enteral feeds) and medications
(number and types of medications were recorded only
for the last two weeks of life to reduce the time burden
related to reviewing the medical records); (5) symptoms
(presence of various symptoms); (6) hospital and
community healthcare utilisation (hospital days and ad-
missions, days spent at home, number of days and
hours, and types of care provided by community
services). We also assessed whether the treatment ap-
proach was documented as palliative care and whether
this approach changed during the last four weeks of life.
A diagnostic chapter and code from the International
Statistical Classification of Diseases and Related Health
Problems (ICD), 10th Revision, online version 2016 [20]
was assigned to each patient, based on the exact diag-
nostic information extracted from the patient’s last med-
ical report. Coding was done by two independent
appraisers to establish reliability and any discrepancies
were discussed until there was consensus about the
diagnosis. All symptoms documented in the patient’s
chart were recorded during data collection. The ones
most frequently reported were grouped into 20 symp-
toms categories, based on symptoms most frequently
reported in the literature [8, 14, 21]. Symptoms that
affected similar areas, e.g. spasticity/dystonia for muscu-
lar impairments, or agitation/irritability for behavioural
problems, were grouped.
Statistical analysis
Descriptive statistics (measures of central tendency and
dispersion, frequencies and percentages) were used to
explore and summarize all variables. A binary logistic
model with likelihood ratio statistics was utilised for
two-tailed comparisons between the diagnostic groups
of variables with a binominal response (Yes – No). For
count outcome variables, negative binomial regression
was utilised to adjust for overdispersion [22]. For vari-
ables with a categorical response, equivalence of propor-
tions between diagnostic groups was tested in
contingency tables using the Pearson’s chi-square test or
Fisher’s exact test when cell sizes were < 5. No measures
of missing value replacement were pursued. Due to the
multiple comparisons performed, we set a conservative
p-value of < 0.001 to indicate statistical significance. Stat-
istical analyses were performed using IBM© SPSS© Sta-
tistics 21 for Mac® (IBM Corp, Armonk, NY, USA).
Results
Of the 307 eligible families, 267 could be contacted and
were invited to participate in the PELICAN study. Of
those, 147 families (55%) consented. Two families lost
twins resulting in a study sample of 149 neonates,
children and adolescents (Table 1). With neonates com-
prising 38% of the sample, the median age at death was
0.5 years for the entire sample but substantially higher
(Mdn = 8.4, range = 1.7 -17.4 years) for the oncology
group. The neonates' median age was 5 days (range = 1 -
26) and substantially lower than age in the other diag-
nostic groups (Table 1). Seven ICD-10 diagnostic chap-
ters were represented in our four groups’ categorisation,
with the highest variety found within the neurology
group. The median time between diagnosis of the life-
limiting CCC (made after birth) and death for the total
sample was one month (interquartile range [IQR], 0 –
6). Within the four groups, the median time between
diagnosis and death was longest for the neurology group
(Mdn = 6 months, IQR = 3 – 29). Diagnoses made
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prenatally, were significantly more frequent in the cardi-
ology group compared to the other groups (p = < 0.001)
and not present in the oncology group. Information re-
lated to gestational age was missing for 5 neonates
(8.8%) and information related to diagnoses made pre-
natally for 2 patients (1.3%) (Table 1).
Place and circumstances of death
Ninety-three patients (62%) died in an intensive care
unit (ICU), with the highest proportion of ICU deaths
occurring in the neonatology group (Table 2). Twenty-f-
ive patients (17%) died at home, with the highest
proportion of home deaths occurring in the oncology
group. Twenty-six patients (17%) received cardiopulmo-
nary resuscitation (CPR) within 24 h before death,
despite 15 patients (17%, n = 147) had a documented
DNR order. A DNR order was documented in 91 pa-
tients’ charts (62%). Of those, 51 patients (57%) had a
change of the DNR order within the last four weeks of
life. This change occurred most frequently in the neo-
natology group (Table 2), often within hours before the
child’s death. For 78 patients (84%) of the 93 who died
in an ICU, death was preceded by a decision to withdraw
life-sustaining interventions.
Interventions, medication and symptoms
Patients underwent several interventions, suffered from
a variety of symptoms, and received a considerable
amount of medication, as documented in their charts.
This information is detailed in Table 3 and Fig. 1. Fif-
ty-one patients (34%) received anaesthesia at least once
Table 1 Demographic and diagnostic patient characteristics
Characteristics Total
N = 149
(100%)
Cardiology
n = 19
(13%)
Neonatology
n = 57
(38%)
Neurology
n = 36
(24%)
Oncology
n = 37
(25%)
Age at death, Mdn (range)
in months 6 (0 – 209) 6 (1 – 109) Na 19 (1 – 207) 101 (20 – 209)
in years 0.5 (0.0 – 17.4) 0.5 (0.1 – 9.1) Na 1.6 (0.1 – 17.2) 8.4 (1.7 – 17.4)
Gender, n (%)
Female 72 (48) 10 (53) 32 (56) 15 (42) 15 (40)
Male 77 (52) 9 (47) 25 (44) 21 (58) 22 (60)
ICD-10 chapter, description, n (%)
II Neoplasms 36 (24) 0 (0) 0 (0) 0 (0) 36 (97)
III Blood/immune system 1 (1) 0 (0) 0 (0) 0 (0) 1 (3)a
IV Endocrine, nutritional, metabolic 6 (4) 0 (0) 0 (0) 6 (16) 0 (0)
VI Nervous system 21 (14) 0 (0) 2 (4) 19 (53) 0 (0)
IX Circulatory systemb 5 (3) 4 (21) 0 (0) 1 (3) 0 (0)
XVI Conditions originating in perinatal period 45 (30) 0 (0) 44 (77) 1 (3) 0 (0)
XVII Congenital, chromosomal 35 (24) 15 (79) 11 (19) 9 (25) 0 (0)
Gestational age (for the neonatology group only) n = 52c
24 0/7 – 27 6/7 Na Na 17 (33) Na Na
28 0/7 – 31 6/7 Na Na 8 (15) Na Na
32 0/7 – 36 6/7 Na Na 9 (17) Na Na
37 0/7 - > 42 0/7 Na Na 18 (35) Na Na
Time since diagnosisd
in days, Mdn (range) Na Na 4 (1 – 26) Na Na
in months, Mdn (range) 1 (0 – 205) 7 (0 - 66) Na 9 (0 - 205) 4 (0 - 139)
in years, Mdn (range) 0 (0 – 17) 0.5 (0.5 – 5.5) Na 0.5 (0.0 – 17.0) 0.5 (0.0 – 12.0)
Diagnosis made prenatally n = 147c n = 34c
Yes, n (%) 31 (21) 11 (58) 13 (23) 7 (21) 0 (0)
Na Not applicable, ICD-10 International Classification of Diseases, 10th Revision
aAplastic anaemia
bStroke included
cInformation was missing for some cases
dCalculated from date of birth, even if diagnosis was suspected prenatally
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during their last four weeks of life, some patients more
than once and for different interventions. The most
commonly documented interventions requiring anaes-
thesia were surgical interventions in 28 patients (55% of
the 51 patients who received anaesthesia) and diagnostic
procedures, e.g. imaging in 27 patients (53%). The over-
all median and mean number of medications with orders
for standard daily doses and as-needed orders rose from
9 (range = 0 - 42), 12 (SD = 9.20) respectively during the
second-to-last week to 12 (range = 1 – 46), 14 (SD =
9.15) respectively during the last week. For 133 patients
(89%) the last treatment approach was documented as
palliative. The approach changed from curative to pallia-
tive during the last month in 88 patients (59%), most
commonly in the neonatology group and least com-
monly in the oncology group (90% vs. 32%, p = < 0.001).
Information was missing for six variables related to in-
terventions and medication and ranged between 0.7%
and 2.7% (Table 3).
Pain was the most frequently documented symptom,
and occurred in 110 patients (78%, N = 141), with no
significant differences between the diagnostic groups.
One hundred and forty patients (95%, N = 148) received
some pain medication, most commonly opioids (93%),
followed by paracetamol (67%). Other common
symptoms included breathing problems (n = 107, 72%),
followed by behavioural problems such as agitation or
irritability (n = 89, 60%). Some symptoms, such as
respiratory secretion, fever, nausea/vomiting, coughing,
sweating, fatigue, drowsiness, anxiety (including worry
and sadness), and poor appetite, differed significantly
(p = < 0.001) between the diagnostic groups (Figure 1).
Overall, an average of 6.42 (SD = 3.14) symptoms were
recorded per patient. Significantly fewer symptoms
were reported in neonates (M = 4.39, SD = 2.15) com-
pared to all other groups (p = < 0.001).
Hospital and community healthcare utilisation
Overall, our study patients stayed in the hospital for a me-
dian of six days (IQR = 2 – 19) during their last four weeks
of life, with the highest number of hospital days for pa-
tients in the cardiology group (Table 4). Nineteen patients
(13%) had no hospital days: 11 of them (58%) from the on-
cology group, 5 (26%) from the neurology group, 3 (16%)
from the cardiology group, and none from the neonat-
ology group. Among the 130 patients who had at least one
hospital day, 62 patients (48%) had one hospital admis-
sion, 10 patients (8%), and 2 patients (1%) had 3 admis-
sions during the last four weeks of life. Fifty-six patients
(43%) had zero hospital admissions, meaning that those
patients were hospitalised at the beginning of data collec-
tion and remained there until their death or discharge. Of
the 57 patients in the neonatology group, 23 patients
(40%) were born in a hospital with no ICU and had to be
transferred to a referral tertiary hospital with an ICU. Pa-
tients from the other diagnostic groups were most com-
monly admitted from home (Table 4).
Table 2 Place and circumstances of death
Total
N = 149
(100%)
Cardiology
n = 19
(13%)
Neonatology
n = 57
(38%)
Neurology
n = 36
(24%)
Oncology
n = 37
(25%)
p-value
Place of death, n (%) < 0.001a
PICU 63 (42) 13 (67) 27 (48) 13 (36) 10 (27)
NICU 30 (20) 0 (0) 27 (48) 3 (8) 0 (0)
Hospital ward / long-term institution 26 (18) 2 (11) 0 (0) 13 (36) 11 (30)
Home 25 (17) 2 (11) 2 (3) 7 (20) 14 (38)
Emergency department / Transport 5 (3) 2 (11) 1 (1) 0 (0) 2 (5)
CPRb
Yes, n (%) 26 (17) 7 (37) 6 (11) 7 (19) 6 (16) 0.097c
DNR order
Yes, n (%) 91 (62) 11 (58) 20 (35) 33 (92) 27 (77) < 0.001c
DNR order change within the last four weeks of life
Yes, n (%) 51 (57) 7 (64) 18 (90) 13 (41) 13 (48) 0.002c
Withdrawal of life-sustaining interventionsd n = 93 n = 13 n = 54 n = 16 n = 10
Yes, n (%) 78 (84) 10 (77) 49 (91) 12 (75) 7 (70) 0.203c
PICU Paediatric intensive care unit, NICU Neonatal intensive care unit, CPR Cardiopulmonary resuscitation, DNR Do not resuscitate
aAcross the four groups, based on Fisher’s exact test
bWithin 24 h before death
cAcross the four groups, based on likelihood ratio chi-square
dOnly applies to patients who died in an intensive care unit
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Seventy-two patients (48%) stayed at home for at least
one day, with patients from the oncology group having
the highest number of home days (Mdn = 24, IQR = 4 -
28), followed by patients from the neurology group (Mdn
= 21, IQR = 4 - 26). Of the 72 patients who stayed at home,
36 (50%) received professional care from a community-
based service. The provision of education and support to
empower the family was the most commonly provided
service, as documented by the care provider, and patients
from the neurology group received more care hours than
patients from the other groups (Table 4).
Discussion
There are several principal findings in this nationwide
study examining patterns of care at EOL in four distinct
diagnostic groups: patients had a variety of primary diag-
noses, covering seven different ICD-10 diagnostic
chapters; 62% of all patients died in ICUs, with 84% of
them following a decision to withdraw life-sustaining
treatment; reliance on invasive medical interventions was
prevalent and patients were exposed to multiple medica-
tions; patients experienced many symptoms with an
average of six symptoms per patient; finally, community-
based health care services were involved in only half of
the cases of the 72 patients (48%) of patients who spent
time at home during their last four weeks of life.
Strengths and limitations
The study provides a wide-ranging overview of current
EOL care practices in a heterogeneous real-life setting of
hospitals, long-term institutions and community health-
care organisations. The inclusion of patients with all
major diagnoses leading to disease- and prematurity-
related infant and childhood deaths, as well as compari-
sons across the diagnostic groups, provides additional
insight and understanding for healthcare professionals.
Previous studies in this field have frequently been
limited to the hospital setting [1, 3] or to a specific diag-
nostic group [8, 14, 15]. Our study is limited by its
cross-sectional, primarily descriptive design incorporat-
ing a retrospective chart review. This approach does not
allow conclusions to be drawn about care quality and
quality of life at the EOL. Generalisability is further lim-
ited by the way that EOL care is often delivered in
Switzerland. Specialised PC/EOL care was offered in
only 3 of the 13 hospitals where data were collected, and
no children’s hospices exist in Switzerland. The study’s
definition of EOL care as the last four weeks of life is
Table 3 Interventions and medications during the last four weeks of life
Total
N = 149
(100%)
Cardiology
n = 19
(13%)
Neonatology
n = 57
(38%)
Neurology
n = 36
(24%)
Oncology
n = 37
(25%)
p-value
Interventions requiring anaesthesia n = 148a n = 35a
Yes, n (%) 51 (34) 11 (58) 21 (37) 6 (17) 13 (35) 0.021b
Mechanical ventilation
Yes, n (%) 94 (63) 14 (74) 55 (97) 15 (42) 10 (27) < 0.001b
ECMO
Yes, n (%) 7 (5) 4 (21) 3 (5) 0 (0) 0 (0) < 0.001b
Presence of CAD n = 148a n = 36a
Yes, n (%) 106 (72) 14 (74) 55 (97) 12 (33) 25 (69) < 0.001b
Enteral feeds via nasogastric or gastrostomy tube n = 148a n = 35a
Yes, n (%) 114 (77) 17 (90) 51 (90) 33 (94) 13 (35) < 0.001b
Medication count in the last week of lifec n = 146a n = 35a n = 35a
Mdn, (range) 12 (1 - 46) 19 (3 - 45) 12 (1 - 34) 10 (3 - 39) 13 (4 - 46) 0.006b
Mean, (SD) 14 (9.15) 21 (11.73) 12 (7.02) 13 (8.82) 15 (9.69)
Pain medication n = 148a n = 35a
Yes, n (%) 140 (95) 18 (95) 54 (95) 33 (94) 35 (95) 1.000b
Anxiolytic medication n = 145a n = 35a n = 34a
Yes, n (%) 84 (58) 14 (74) 27 (47) 18 (51) 25 (74) 0.032b
Antiemetic medication n = 146a n = 35a n = 35a
Yes, n (%) 25 (17) 2 (11) 0 (0) 0 (0) 23 (66) < 0.001b
ECMO Extracorporeal membrane oxygenation, CAD Central access device, either venous or arterial
aInformation was missing for some cases
bAcross the four groups, based on likelihood ratio chi-square
cIncludes both standing daily dosages and as-needed orders
Zimmermann et al. BMC Pediatrics  (2018) 18:67 Page 6 of 10
somehow artificial, yet was justified by the literature, ex-
perts’ opinion and feasibility constraints. The study,
therefore, provides insight in paediatric EOL care in a
limited time frame, not necessarily covering all aspects
of EOL care across a broader time period. Known reli-
ability issues related to chart reviews were kept to a
minimum by utilising established and appropriate mea-
sures, resulting in few discrepancies in the data col-
lected. However, the mixed quality of documentation
among healthcare personnel, resulting in incomplete or
missing data independent of data collection quality still
limits the study’s reliability [19]. The comparisons be-
tween the four major diagnostic groups highlight
elements that warrant discussion.
Medication and symptoms
Medication counts in our study were high, with an overall
mean of 14 drugs or as-needed medication orders during
the last week of life. This number is higher than the re-
ported average of 9 drugs in a study involving 515 paediat-
ric patients with a similar diagnostic profile receiving PPC
[3]. A similar average number of 13.9 (SD = 8.9) of medi-
cations used in the last week of life was reported in a study
of 30 children dying in an Australian hospital in 2001.
Two thirds of the 30 children died in the ICU, which
might have influenced the high numbers found in this
study [23]. We found that the medication count increased
from the second-to-last week to the last week of life. Thus,
it seems that the intensity of medical treatment increases
as the child nears death, a phase which is accompanied by
a greater need for pharmacological interventions, espe-
cially for relieving pain, based on our clinical experience.
The high number of medications in the cardiology group
was often due to the frequent need for CPR and a high
prevalence of surgical interventions, which are also de-
scribed in other studies with cardiology patients [15, 21].
Although not perfectly comparable, symptom type and
prevalence differed from the aforementioned study of 515
patients receiving PPC, in which pain was only the sixth
most frequent symptom extracted from patients’ charts
[3]. However, pain has been reported to be the most fre-
quent symptom in other studies with various paediatric
cohorts in PC or EOL care [8, 14]. Our study adds to
existing knowledge by demonstrating that symptom
prevalence is dependent on the underlying CCC and that
it can differ considerably.
Hospital and community healthcare utilisation
Most patients (n = 130) stayed at least one day in hospital
during their last four weeks of life. Of those, 62 patients
(48%) had at least one hospital admission and 10 patients
(8%) had more than one admission. This is a lower per-
centage than reported in a recent North American study
about trends in high-intensity EOL care among children
with cancer [24]. In this population-based study with a co-
hort of 815 children diagnosed with cancer who died
between 2000 and 2012, 143 patients (17.6%) of the pa-
tients had more than one hospital admission within
30 days of death. Compared with our oncology sub-group
(n = 37), twenty-six patients stayed at least one day in hos-
pital and 3 (11%) of them had more than one admission
during their last four weeks of life.
Slightly less than 50% of our study’s patients were at
home at some point during their last four weeks of life.
Naturally, this was the case for very few neonates. In
light of the probably growing rate of prenatal diagnosis
of a life-limiting CCC, early initiation of PPC may allow
better planning and implementation of specialised care
services at home [25]. Perinatal palliative care is an even
younger specialty than PPC [25] and was not integrated
in the three PPC programmes in Switzerland. A recent
survey about the provision of services showed that
perinatal palliative care programmes in the US were
based in academic medical centres, regional and local
hospitals, or community based hospitals [26]. Back in
Fig. 1 Symptom prevalence and comparison between the four diagnostic
groups. ** = p-value < 0.001 based on a negative binomial regression
model.aAdjusted for mechanical ventilation. bAdjusted for enteral feeds.
cNeonatology group excluded due to 0% of symptom presence
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2013, Feudtner et al. [13] showed however, that only
54% of hospital-based PPC programmes provided pre-
natal consultation [13].
Only half of the patients who spent time at home re-
ceived community-based healthcare services. Recent
data from Germany and the US show that the coordin-
ation and provision of specialised palliative home care
can alleviate caregivers’ distress and burden [27], and
improve both the child’s [28] and the caregivers’ quality
of life [27]. As reported by our study, community nurs-
ing care encompasses a range of service types. The high
level of coordination with the leading team in the hos-
pital and the expertise required makes it especially chal-
lenging. Subgroup analysis of our study’s at-home
population targeting facilitators for and barriers to EOL
care in the home setting has been performed and is
published elsewhere [29].
Implications
PPC is growing internationally and the provision of con-
sultation by a hospital-based multiprofessional PPC team
seems to be the favoured model of care [13]. There is
some evidence suggesting that PPC programmes provid-
ing specialised services may reduce healthcare resource
utilisation by reducing hospital admissions, shortening
hospital stays, and lessening aggressive care to prolong
life [30]. Additionally, provision of hospital-based specia-
lised PPC may shift and extend the care setting beyond
the hospital [30]. In order to provide good quality EOL
care a high level of expertise with a good understanding
of the different illness trajectories, and efficient collabor-
ation across a variety of paediatric subspecialties is re-
quired. Outcome measurement has to be introduced
into practice and prospective studies are needed to
evaluate meaningful family-oriented clinical outcomes,
quality of care, and the impact of specialised PPC to
advance clinical practice and research in the field [30, 31].
Conclusions
Swiss paediatric patients, similar to what is reported
from other countries, experience high-intensity EOL
care with invasive interventions, high medication counts
Table 4 Hospital and community healthcare utilisation during the last four weeks of life
Total
N = 149
(100%)
Cardiology
n = 19
(13%)
Neonatology
n = 57
(38%)
Neurology
n = 36
(24%)
Oncology
n = 37
(25%)
p-value
Hospital days, Mdn (range) 6 (0 - 28) 20 (0 - 28) 5 (1 - 26) 7 (0 - 28) 4 (0 - 28) 0.035a
Care setting before hospital admissionb, n (%) n = 88 n = 17 n = 23 n = 26 n = 22
Home 37 (42) 11 (64) 0 (0) 16 (62) 10 (45) NAc
Other hospital 35 (40) 3 (18) 23 (100) 4 (15) 5 (23) NAc
Emergency department 8 (9) 3 (18) 0 (0) 4 (15) 1 (5) NAc
Outpatient clinic 7 (8) 0 (0) 0 (0) 1 (4) 6 (27) NAc
Long-term institution 1 (1) 0 (0) 0 (0) 1 (4) 0 (0) NAc
Patients at home at least for one day, n (%) 72 (48) 11 (58) 3 (5) 27 (75) 31 (84) < 0.001a
Days spent at home, Mdn (range) 0 (0 - 28) 8 (0 - 28) 0 (0 - 16) 21 (0 - 28) 24 (0 - 28) 0.001a
Care days with community care serviced, n = 72 n = 11 n = 3 n = 27 n = 31
Mdn (range) 1 (0 - 28) 0 (0 - 24) 1 (0 - 5) 5 (0 - 28) 0 (0 - 28) 0.001a
Hours of care by community care serviced n = 36 n = 5 n = 2 n = 15 n = 14
Mdn (range) 34 (2 - 315) 12 (7 - 190) 6 (3 - 8) 38 (4 - 315) 23 (2 - 108) 0.111a
Type of community care service
Family education/support, n (%) 35 (97) 5 (100) 2 (100) 14 (93) 14 (100) NAc
Needs assessment, n (%) 31 (86) 4 (80) 1 (50) 13 (87) 13 (93) NAc
Monitoring of vital signs/general condition, n (%) 29 (81) 5 (100) 2 (100) 13 (87) 9 (64) NAc
Administration of medication, n (%) 25 (69) 5 (100) 0 (0) 10 (67) 10 (71) NAc
Interventions related to enteral feeds, n (%) 22 (61) 5 (100) 1 (50) 13 (87) 3 (21) NAc
Respiratory interventions, n (%) 18 (50) 2 (40) 0 (0) 11 (73) 5 (36) NAc
Interventions related to excretion, n (%) 14 (39 1 (20) 0 (0) 6 (40) 7 (50) NAc
NA Not applicable
aAcross the four groups, based on likelihood ratio chi-square
bRepresenting the cumulative hospital admissions in all patients
cNo significance testing conducted due to small numbers
dConsisting of nurses, most of them specialised in paediatric and/or community nursing
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and high symptom prevalence. Transitions between the
inpatient and the home care setting were experienced by
most patients outside the neonatology group. Profes-
sional home care was only utilised by half of the pa-
tients/families. The provision of specialised palliative
and EOL care services, including the capacity of com-
munity healthcare services were limited. There is there-
fore a need for PPC services to be expanded to meet the
specific needs of seriously ill children and their families
in Switzerland.
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